Silencing of LIMD1 promotes proliferation and reverses cell adhesion‑mediated drug resistance in non‑Hodgkin's lymphoma

Tang,Jie; Zhu,Liqun; Huang,Yuejiao; Shi,Bing; Zhang,Shuqing; Gu,Lingli; Zhao,Jie; Deng,Minghao; Zhu,Jiahao; Xun,He; Wang,Yuchan; Wang,Chun

doi:10.3892/ol.2019.9921

Silencing of LIMD1 promotes proliferation and reverses cell adhesion‑mediated drug resistance in non‑Hodgkin's lymphoma

Authors:
- Jie Tang
- Liqun Zhu
- Yuejiao Huang
- Bing Shi
- Shuqing Zhang
- Lingli Gu
- Jie Zhao
- Minghao Deng
- Jiahao Zhu
- He Xun
- Yuchan Wang
- Chun Wang
View Affiliations

Affiliations: Department of Oncology, Liyang People's Hospital, Liyang, Jiangsu 213300, P.R. China, Department of Oncology, Affiliated Cancer Hospital of Nantong University, Nantong, Jiangsu 226002, P.R. China, Department of Oncology, The Second People's Hospital of Nantong, Nantong, Jiangsu 226002, P.R. China, Department of Pathogenic Biology, Medical College, Nantong University, Nantong, Jiangsu 226002, P.R. China
Published online on: January 11, 2019 https://doi.org/10.3892/ol.2019.9921
Pages: 2993-3000

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

LIM domains‑containing protein 1 (LIMD1) is a tumor suppressor protein downregulated in numerous solid malignancies. However, the functional role of LIMD1 in non‑Hodgkin's lymphoma (NHL) remains unclear. In the present study, it was demonstrated that LIMD1 is associated with the proliferation of NHL and cell adhesion mediated‑drug resistance (CAM‑DR). It was indicated by western blot analysis that LIMD1expression is lower in progressive lymphoma compared with indolent lymphoma. Furthermore, it was indicated that the role of LIMD1 in cell viability and proliferation remains unclear. Finally, the present study demonstrated that LIMD1 serves an important role in CAM‑DR by regulating cell cycle progression. Silencing of LIMD1 may reverse CAM‑DR in NHL. Therefore, the findings of the present study suggested that LIMD1 may be a potential therapeutic target for patients with NHL.

View Figures

View References

1	Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P, Ferguson SM, Mandelkern T, Zheng M, Xu T, et al: Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-hodgkin lymphoma. Blood. 129:1768–1778. 2017. View Article : Google Scholar : PubMed/NCBI
2	Riley SN: Investigating the multivariate nature of NHL player performance with structural equation modeling. PLoS one. 12:e01843462017. View Article : Google Scholar : PubMed/NCBI
3	Yin H, Miao X, Wu Y, Wei Y, Zong G, Yang S, Chen X, Zheng G, Zhu X, Guo Y, et al: The role of the chaperonin containing t-complex polypeptide 1, subunit 8 (CCT8) in B-cell non-hodgkin's lymphoma. Leuk Res. 45:59–67. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zhu X, Miao X, Wu Y, Li C, Guo Y, Liu Y, Chen Y, Lu X, Wang Y and He S: ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in non-hodgkin's lymphomas. Exp Cell Res. 335:216–223. 2015. View Article : Google Scholar : PubMed/NCBI
5	Hazlehurst LA and Dalton WS: Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 20:43–50. 2001. View Article : Google Scholar : PubMed/NCBI
6	Landowski TH, Olashaw NE, Agrawal D and Dalton WS: Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 22:2417–2421. 2003. View Article : Google Scholar : PubMed/NCBI
7	Miao X, Xu X, Wu Y, Zhu X, Chen X, Li C, Lu X, Chen Y, Liu Y, Huang J, et al: Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-hodgkin's lymphoma. Tumour Biol. 37:1369–1378. 2016. View Article : Google Scholar : PubMed/NCBI
8	Nakagawa Y, Nakayama H, Nagata M, Yoshida R, Kawahara K, Hirosue A, Tanaka T, Yuno A, Matsuoka Y, Kojima T, et al: Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells. Int J Oncol. 44:1376–1384. 2014. View Article : Google Scholar : PubMed/NCBI
9	Hou X, Li T, Ren Z and Liu Y: Novel BRCA2-interacting protein, LIMD1, is essential for the centrosome localization of BRCA2 in esophageal cancer cell. Oncol Res. 24:247–253. 2016. View Article : Google Scholar : PubMed/NCBI
10	Sharp TV, Al-Attar A, Foxler DE, Ding L, de A Vallim TQ, Zhang Y, Nijmeh HS, Webb TM, Nicholson AG, Zhang Q, et al: The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development. Proc Natl Acad Sci USA. 105:19932–19937. 2008. View Article : Google Scholar : PubMed/NCBI
11	Spendlove I, Al-Attar A, Watherstone O, Webb TM, Ellis IO, Longmore GD and Sharp TV: Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival. Int J Cancer. 123:2247–2253. 2008. View Article : Google Scholar : PubMed/NCBI
12	Huggins CJ, Gill M and Andrulis IL: Identification of rare variants in the hLIMD1 gene in breast cancer. Cancer Genet Cytogenet. 178:36–41. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kiss H, Kedra D, Yang Y, Kost-Alimova M, Kiss C, O'Brien KP, Fransson I, Klein G, Imreh S and Dumanski JP: A novel gene containing LIM domains (LIMD1) is located within the common eliminated region 1 (C3CER1) in 3p21.3. Hum Genet. 105:552–559. 1999. View Article : Google Scholar : PubMed/NCBI
14	Huggins CJ and Andrulis IL: Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers. Cancer Lett. 267:55–66. 2008. View Article : Google Scholar : PubMed/NCBI
15	Mayank AK, Sharma S, Deshwal RK and Lal SK: LIMD1 antagonizes E2F1 activity and cell cycle progression by enhancing Rb function in cancer cells. Cell Biol Int. 38:809–817. 2014. View Article : Google Scholar : PubMed/NCBI
16	Hang Q, Fei M, Hou S, Ni Q, Lu C, Zhang G, Gong P, Guan C, Huang X and He S: Expression of Spy1 protein in human non-Hodgkin's lymphomas is correlated with phosphorylation of p27 Kip1 on Thr187 and cell proliferation. Med Oncol. 29:3504–3514. 2012. View Article : Google Scholar : PubMed/NCBI
17	Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ and Dalton WS: Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 19:4319–4327. 2000. View Article : Google Scholar : PubMed/NCBI
18	Sarkar S, Maiti GP, Jha J, Biswas J, Roy A, Roychoudhury S, Sharp T and Panda CK: Reduction of proliferation and induction of apoptosis are associated with shrinkage of head and neck squamous cell carcinoma due to neoadjuvant chemotherapy. Asian Pac J Cancer Prev. 14:6419–6425. 2013. View Article : Google Scholar : PubMed/NCBI
19	Huang X, Wang Y, Nan X, He S, Xu X, Zhu X, Tang J, Yang X, Yao L, Wang X and Cheng C: The role of the orphan G protein-coupled receptor 37 (GPR37) in multiple myeloma cells. Leuk Res. 38:225–235. 2014. View Article : Google Scholar : PubMed/NCBI
20	Damiano JS, Cress AE, Hazlehurst LA, Shtil AA and Dalton WS: Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 93:1658–1667. 1999.PubMed/NCBI
21	Chen Z, Zhu X, Xie T, Xie J, Quo K and Liu X: Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma. Oncol Lett. 8:795–798. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, Roy B, Roychoudhury S and Panda CK: Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis. Int J Cancer. 123:2594–2604. 2008. View Article : Google Scholar : PubMed/NCBI
23	Ghosh S, Ghosh A, Maiti GP, Mukherjee N, Dutta S, Roy A, Roychoudhury S and Panda CK: LIMD1 is more frequently altered than RB1 in head and neck squamous cell carcinoma: Clinical and prognostic implications. Mol Cancer. 9:582010. View Article : Google Scholar : PubMed/NCBI
24	Tang J, Ji L, Wang Y, Huang Y, Yin H, He Y, Liu J, Miao X, Wu Y, Xu X, et al: Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells. Int J Hematol. 102:25–34. 2015. View Article : Google Scholar : PubMed/NCBI
25	Ouyang Y, Zhong F, Wang Q, Ding L, Zhang P, Chen L, Wang Y and Cheng C: DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas. Leuk Res. 50:104–111. 2016. View Article : Google Scholar : PubMed/NCBI
26	Balsas P, Palomero J, Eguileor Á, Rodríguez ML, Vegliante MC, Planas-Rigol E, Sureda-Gómez M, Cid MC, Campo E and Amador V: SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 130:501–513. 2017. View Article : Google Scholar : PubMed/NCBI
27	Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, et al: Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: Therapeutic implications. Leukemia. 28:373–383. 2014. View Article : Google Scholar : PubMed/NCBI
28	Tsubaki M, Takeda T, Yoshizumi M, Ueda E, Itoh T, Imano M, Satou T and Nishida S: RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines. Tumour Biol. 37:9099–9110. 2016. View Article : Google Scholar : PubMed/NCBI
29	Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, et al: CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Br J Haematol. 179:36–49. 2017. View Article : Google Scholar : PubMed/NCBI
30	Foxler DE, James V, Shelton SJ, Vallim TQ, Shaw PE and Sharp TV: PU.1 is a major transcriptional activator of the tumour suppressor gene LIMD1. FEBS Lett. 585:1089–1096. 2011. View Article : Google Scholar : PubMed/NCBI
31	Zhao MK, Wang Y, Murphy K, Yi J, Beckerle MC and Gilmore TD: LIM domain-containing protein trip6 can act as a coactivator for the v-Rel transcription factor. Gene Exp. 8:207–217. 1999.